Cargando…

The detection rate of methylene blue combined with another tracer in sentinel lymph node biopsy of early-stage breast cancer: a systematic review and network meta-analysis

BACKGROUND: Methylene blue (MB) alone or combined with 99mtechnetium-labeled sulphur colloid (Tc99m) or indocyanine green (ICG) is widely used for sentinel lymph node biopsy (SLNB) of early-stage breast cancer in developing countries and regions. However, studies investigating the effectiveness of M...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hong-Jin, Sun, Ming-Shuai, Liu, Li-Yuan, Yu, Zheng-Heng, Chen, Xiao-Xi, Liu, Qian, Cheng, Yuan-Jia, Xu, Ling, Liu, Yin-Hua, Ye, Jing-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798807/
https://www.ncbi.nlm.nih.gov/pubmed/35116372
http://dx.doi.org/10.21037/tcr-21-1239
_version_ 1784641903293104128
author Liu, Hong-Jin
Sun, Ming-Shuai
Liu, Li-Yuan
Yu, Zheng-Heng
Chen, Xiao-Xi
Liu, Qian
Cheng, Yuan-Jia
Xu, Ling
Liu, Yin-Hua
Ye, Jing-Ming
author_facet Liu, Hong-Jin
Sun, Ming-Shuai
Liu, Li-Yuan
Yu, Zheng-Heng
Chen, Xiao-Xi
Liu, Qian
Cheng, Yuan-Jia
Xu, Ling
Liu, Yin-Hua
Ye, Jing-Ming
author_sort Liu, Hong-Jin
collection PubMed
description BACKGROUND: Methylene blue (MB) alone or combined with 99mtechnetium-labeled sulphur colloid (Tc99m) or indocyanine green (ICG) is widely used for sentinel lymph node biopsy (SLNB) of early-stage breast cancer in developing countries and regions. However, studies investigating the effectiveness of MB combined with another tracer have produced heterogeneous results. The purpose of this network meta-analysis (NMA) was to evaluate the detection rate of MB alone, MB + Tc99m, and MB + ICG, and to examine the differences between the 3 methods. METHODS: We conducted a comprehensive electronic literature search on the PubMed, Embase, Web of Science, CNKI, and Wanfang Data databases from inception to October 2021. The meta-analysis included 7,498 patients in 49 studies. The risk of bias for each study was independently assessed as low, moderate, or high using criteria adapted from the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. Fixed- and random-effects models were used to calculate pooled estimates. Mixed-comparison analysis using random-effects models. We assessed statistical heterogeneity by I2 statistics and evaluated publication bias using Begg’s test. RESULTS: The identification rate (IR), false-negative rate (FNR), sensitivity (SEN), and accuracy rate (AR) using MB + Tc99m were 96%, 7%, 93%, and 96%, respectively; the IR, FNR, SEN, and AR using MB + ICG were 97%, 7%, 93%, and 97%, respectively. The NMA found that IR and AR between MB + ICG and MB + Tc99m was OR =1.37 (95% CI: 0.41–4.20) and OR =1.33 (95% CI: 0.56–3.32), respectively. DISCUSSION: Our results are similar to those of most previous studies, and meta-analysis showed that the MB + Tc99m or MB + ICG mapping methods can be used to obtain higher IR and lower FNR than MB alone. Our NMA showed no statistical significance between MB + Tc99m and MB + ICG with IR and AR. Both MB + Tc99m and MB + ICG can be used as effective mapping methods in SLNB of early-stage breast cancer to improve the detection rate.
format Online
Article
Text
id pubmed-8798807
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87988072022-02-02 The detection rate of methylene blue combined with another tracer in sentinel lymph node biopsy of early-stage breast cancer: a systematic review and network meta-analysis Liu, Hong-Jin Sun, Ming-Shuai Liu, Li-Yuan Yu, Zheng-Heng Chen, Xiao-Xi Liu, Qian Cheng, Yuan-Jia Xu, Ling Liu, Yin-Hua Ye, Jing-Ming Transl Cancer Res Original Article BACKGROUND: Methylene blue (MB) alone or combined with 99mtechnetium-labeled sulphur colloid (Tc99m) or indocyanine green (ICG) is widely used for sentinel lymph node biopsy (SLNB) of early-stage breast cancer in developing countries and regions. However, studies investigating the effectiveness of MB combined with another tracer have produced heterogeneous results. The purpose of this network meta-analysis (NMA) was to evaluate the detection rate of MB alone, MB + Tc99m, and MB + ICG, and to examine the differences between the 3 methods. METHODS: We conducted a comprehensive electronic literature search on the PubMed, Embase, Web of Science, CNKI, and Wanfang Data databases from inception to October 2021. The meta-analysis included 7,498 patients in 49 studies. The risk of bias for each study was independently assessed as low, moderate, or high using criteria adapted from the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. Fixed- and random-effects models were used to calculate pooled estimates. Mixed-comparison analysis using random-effects models. We assessed statistical heterogeneity by I2 statistics and evaluated publication bias using Begg’s test. RESULTS: The identification rate (IR), false-negative rate (FNR), sensitivity (SEN), and accuracy rate (AR) using MB + Tc99m were 96%, 7%, 93%, and 96%, respectively; the IR, FNR, SEN, and AR using MB + ICG were 97%, 7%, 93%, and 97%, respectively. The NMA found that IR and AR between MB + ICG and MB + Tc99m was OR =1.37 (95% CI: 0.41–4.20) and OR =1.33 (95% CI: 0.56–3.32), respectively. DISCUSSION: Our results are similar to those of most previous studies, and meta-analysis showed that the MB + Tc99m or MB + ICG mapping methods can be used to obtain higher IR and lower FNR than MB alone. Our NMA showed no statistical significance between MB + Tc99m and MB + ICG with IR and AR. Both MB + Tc99m and MB + ICG can be used as effective mapping methods in SLNB of early-stage breast cancer to improve the detection rate. AME Publishing Company 2021-12 /pmc/articles/PMC8798807/ /pubmed/35116372 http://dx.doi.org/10.21037/tcr-21-1239 Text en 2021 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Liu, Hong-Jin
Sun, Ming-Shuai
Liu, Li-Yuan
Yu, Zheng-Heng
Chen, Xiao-Xi
Liu, Qian
Cheng, Yuan-Jia
Xu, Ling
Liu, Yin-Hua
Ye, Jing-Ming
The detection rate of methylene blue combined with another tracer in sentinel lymph node biopsy of early-stage breast cancer: a systematic review and network meta-analysis
title The detection rate of methylene blue combined with another tracer in sentinel lymph node biopsy of early-stage breast cancer: a systematic review and network meta-analysis
title_full The detection rate of methylene blue combined with another tracer in sentinel lymph node biopsy of early-stage breast cancer: a systematic review and network meta-analysis
title_fullStr The detection rate of methylene blue combined with another tracer in sentinel lymph node biopsy of early-stage breast cancer: a systematic review and network meta-analysis
title_full_unstemmed The detection rate of methylene blue combined with another tracer in sentinel lymph node biopsy of early-stage breast cancer: a systematic review and network meta-analysis
title_short The detection rate of methylene blue combined with another tracer in sentinel lymph node biopsy of early-stage breast cancer: a systematic review and network meta-analysis
title_sort detection rate of methylene blue combined with another tracer in sentinel lymph node biopsy of early-stage breast cancer: a systematic review and network meta-analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798807/
https://www.ncbi.nlm.nih.gov/pubmed/35116372
http://dx.doi.org/10.21037/tcr-21-1239
work_keys_str_mv AT liuhongjin thedetectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT sunmingshuai thedetectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT liuliyuan thedetectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT yuzhengheng thedetectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT chenxiaoxi thedetectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT liuqian thedetectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT chengyuanjia thedetectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT xuling thedetectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT liuyinhua thedetectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT yejingming thedetectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT liuhongjin detectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT sunmingshuai detectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT liuliyuan detectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT yuzhengheng detectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT chenxiaoxi detectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT liuqian detectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT chengyuanjia detectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT xuling detectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT liuyinhua detectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis
AT yejingming detectionrateofmethylenebluecombinedwithanothertracerinsentinellymphnodebiopsyofearlystagebreastcancerasystematicreviewandnetworkmetaanalysis